Potential Disease‐Modifying Effects of Ganglioside <scp>GM1</scp> Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial
High-dose GM1 treatment significantly ameliorated ataxic symptoms in patients with SCA3. © 2024 International Parkinson and Movement Disorder Society.
Authors
- Y. Chen
- Hai‐Yan Tian (ORCID: https://orcid.org/0000-0002-2421-8712)
- Renyi Feng
- Chi Qin (ORCID: https://orcid.org/0009-0007-5903-7982)
- Hong Jiang (ORCID: https://orcid.org/0000-0003-2812-4120)
- Qingyong Zhu (ORCID: https://orcid.org/0000-0002-7817-3679)
- Dongxiao Liang (ORCID: https://orcid.org/0000-0002-4869-6284)
- Beisha Tang (ORCID: https://orcid.org/0000-0003-2120-1576)
- Rui Zhang (ORCID: https://orcid.org/0000-0003-0699-3077)
- Xuejing Wang (ORCID: https://orcid.org/0000-0003-2908-7763)
- Xinfa Ding (ORCID: https://orcid.org/0000-0002-5528-566X)
- Mingming Ma
- Jiu‐Qi Wang
Institutions
- Central South University (CN)
- Zhengzhou University (CN)
- Henan Provincial People's Hospital (CN)
- First Affiliated Hospital of University of South China (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Third Xiangya Hospital (CN)
- Henan Provincial Center for Disease Control and Prevention (CN)
- University of South China (CN)
- Hunan Institute of Technology (CN)
Publication Details
- Journal
- Movement Disorders
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1002/mds.30050
- Citations
- 2
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- National Natural Science Foundation of China
- Zhengzhou University
- Natural Science Foundation of Henan Province
- First Affiliated Hospital of Zhengzhou University